Suzhou Zelgen Biopharmaceuticals Co., Ltd.

Shanghai Stock Exchange 688266.SS

Suzhou Zelgen Biopharmaceuticals Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2023: -9.65%

Suzhou Zelgen Biopharmaceuticals Co., Ltd. Return on Assets (ROA) is -9.65% for the year ending December 31, 2023, a 66.87% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.

Suzhou Zelgen Biopharmaceuticals Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2022 was -29.13%, a -10.08% change year over year.
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2021 was -26.46%, a -67.81% change year over year.
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2020 was -15.77%, a 88.73% change year over year.
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Return on Assets (ROA) for the year ending December 31, 2019 was -139.88%, a -44.58% change year over year.

Key data

Date	Return on Assets (ROA)	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio

Shanghai Stock Exchange: 688266.SS

Suzhou Zelgen Biopharmaceuticals Co., Ltd.

CEO	Mr. Zelin Sheng
IPO Date	Jan. 23, 2020
Location	China
Headquarters	No. 209, Chenfeng Road
Employees	867
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Vaccines

Description

Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers small molecule and recombinant protein drugs for the treatment of liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, and hepatobiliary diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.

Key trends

Past 5 years